DSP Plans Japan Trials On Targeted Cancer Drug Of BBI Subsidiary
This article was originally published in PharmAsia News
Dainippon Sumitomo Pharma said it plans to begin clinical trials in Japan for two oral cancer drugs, BBI608 and BBI503, considered the world's first to target cancer stem cells.
You may also be interested in...
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.